Promptly and ZEISS VisioGen partner to bring human-verified AI patient engagement to ophthalmology practices

Miami, FL, Thursday, October 8 2026. Promptly Technology, Inc. (Promptly), which offers the most comprehensive all-in-one Patient Experience Suite including the leading Patient Conversion System for specialty medical practices, and ZEISS VisioGen, a human-verified AI patient communication solution from Carl Zeiss India Bangalore Pvt Ltd, today announced a partnership to give U.S. ophthalmology practices one connected path from a patient's first website question to a booked, converted patient.

Ophthalmology practices receive candidacy, cost, and recovery questions through their websites at every hour. Answering those questions well, and then converting the inquiry into a scheduled patient, are two different jobs. This partnership brings together a system for each.

What each company brings

ZEISS VisioGen is the first responsible AI solution for patient engagement in ophthalmology. It answers patient questions submitted through a practice's website, with a ZEISS-trained, licensed optometrist reviewing every reply before the patient sees it. It is built exclusively for ophthalmology, connects with all major practice management and EHR systems, is HIPAA compliant, and is not a medical device. Not another chatbot: a professionally verified patient-engagement service operated for the clinic.

Promptly's Patient Conversion System captures each inquiry into the practice CRM and books, schedules, follows up, and tracks the patient, running on top of the practice management and EHR systems a clinic already uses. Its role is to convert the inquiry and record the outcome.

What the partnership gives practices

Together, the two systems give a practice one governed path: a patient's question is answered under licensed clinical review, then handed to the practice with the intent, context, and next step, where it is booked, followed up, and converted. The practice adds no headcount and keeps the systems it already runs.

Quote

"A lead is only as valuable as the patient experience that follows, because while marketing drives interest, seamless workflows drive conversion. By integrating Promptly’s Patient Conversion System with ZEISS Visiogen's lead generation and clinical review, we are giving practices a unified, end-to-end workflow. Together, we are guiding patients from their initial inquiry all the way to final payment, without the burden of managing multiple systems."

Dr. Anish Kapur, Founder and Chief Executive Officer, Promptly.  

Availability

ZEISS VisioGen and Promptly are available to U.S. ophthalmology practices. Both companies will be at the American Academy of Ophthalmology 2026 annual meeting in New Orleans, October 10 to 12. ZEISS VisioGen is at booth 3719 and Promptly is at booth 1861.

About Promptly

Promptly is an all-in-one Patient Engagement and Experience Suite designed to supercharge existing practice management systems. By automating tedious administrative tasks, Promptly empowers healthcare staff to focus on what matters most: connecting with patients. Our comprehensive platform consolidates multiple software solutions into a single, unified hub featuring online appointment scheduling, digital intake, real-time insurance verification, automated payments, and multi-channel patient communication.

About ZEISS VisioGen

ZEISS VisioGen is the first responsible AI solution for patient engagement in ophthalmology, a human-verified AI patient communication platform from Carl Zeiss India Bangalore Pvt Ltd. Patient questions submitted through a practice's website are drafted by AI against the practice's approved protocols and reviewed by a ZEISS-trained, licensed optometrist before delivery. ZEISS VisioGen connects with all major practice management and EHR systems, is HIPAA compliant, is not a medical device, and is available in the United States.

Media contact

Promptly Marketing, marketing@promptlycheckin.com, (908) 271-8695

Educational and scheduling support only. Not a medical device. Available in the US.